NVS Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of 28.26% compared to Novartis AG's net margin of 16.69%. Novartis AG's return on equity of 33.87% beat AstraZeneca PLC's return on equity of 22.01%.

Novartis AG has a consensus price target of $134.88, signalling downside risk potential of -1.45%. On the other hand AstraZeneca PLC has an analysts' consensus of $98.96 which suggests that it could grow by 8.09%. Given that AstraZeneca PLC has higher upside potential than Novartis AG, analysts believe AstraZeneca PLC is more attractive than Novartis AG.

Novartis AG has a beta of 0.525, which suggesting that the stock is 47.542% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.471%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.92%. AstraZeneca PLC offers a yield of 1.71% to investors and pays a quarterly dividend of $0.52 per share. Novartis AG pays 55.39% of its earnings as a dividend. AstraZeneca PLC pays out 66.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are smaller than AstraZeneca PLC quarterly revenues of $15.1B. Novartis AG's net income of $3.9B is higher than AstraZeneca PLC's net income of $2.5B. Notably, Novartis AG's price-to-earnings ratio is 18.66x while AstraZeneca PLC's PE ratio is 30.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.95x versus 4.92x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 28.26% compared to Novartis AG's net margin of 38.89%. Novartis AG's return on equity of 33.87% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Novartis AG has a consensus price target of $134.88, signalling downside risk potential of -1.45%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 1.35%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Novartis AG, analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Novartis AG.

Novartis AG has a beta of 0.525, which suggesting that the stock is 47.542% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.92%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Novartis AG pays 55.39% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Novartis AG's net income of $3.9B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Novartis AG's price-to-earnings ratio is 18.66x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.95x versus 6.03x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 28.26% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 33.87% beat Roche Holding AG's return on equity of 28.65%.

Novartis AG has a consensus price target of $134.88, signalling downside risk potential of -1.45%. On the other hand Roche Holding AG has an analysts' consensus of $52.84 which suggests that it could grow by 2.83%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.525, which suggesting that the stock is 47.542% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.97%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.92%. Roche Holding AG offers a yield of 2.7% to investors and pays a quarterly dividend of $1.39 per share. Novartis AG pays 55.39% of its earnings as a dividend. Roche Holding AG pays out 58.07% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $3.9B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 18.66x while Roche Holding AG's PE ratio is 30.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.95x versus 4.64x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

Avidity Biosciences, Inc. has a net margin of 28.26% compared to Novartis AG's net margin of -1398.33%. Novartis AG's return on equity of 33.87% beat Avidity Biosciences, Inc.'s return on equity of -37.47%.

Novartis AG has a consensus price target of $134.88, signalling downside risk potential of -1.45%. On the other hand Avidity Biosciences, Inc. has an analysts' consensus of $74.64 which suggests that it could grow by 3.38%. Given that Avidity Biosciences, Inc. has higher upside potential than Novartis AG, analysts believe Avidity Biosciences, Inc. is more attractive than Novartis AG.

Novartis AG has a beta of 0.525, which suggesting that the stock is 47.542% less volatile than S&P 500. In comparison Avidity Biosciences, Inc. has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.581%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 2.92%. Avidity Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 55.39% of its earnings as a dividend. Avidity Biosciences, Inc. pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.9B, which are larger than Avidity Biosciences, Inc. quarterly revenues of $12.5M. Novartis AG's net income of $3.9B is higher than Avidity Biosciences, Inc.'s net income of -$174.4M. Notably, Novartis AG's price-to-earnings ratio is 18.66x while Avidity Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.95x versus 454.32x for Avidity Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.